TransCode Therapeutics is a biopharmaceutical company focused primarily on developing and commercializing drugs and diagnostics for treating and identifying metastatic disease. Co.'s primary therapeutic candidate, TTX-MC138, targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Co.'s other preclinical programs include two solid tumor programs: TTX-siPDL1, a small interfering RNA (siRNA)-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. We show 12 historical shares outstanding datapoints in our coverage of RNAZ's shares outstanding history.
Understanding the changing numbers of RNAZ shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like RNAZ versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching RNAZ by allowing them to research RNAZ shares outstanding history
as well as any other stock in our coverage universe. |
Free RNAZ Email Alerts:
Video: Shares Outstanding Importance
